Presently, of those numbers, if you are looking at the clinical trials that are for a drug development, 20 per cent are phase I studies, 37 per cent are phase II and 43 per cent are phase III, and most of the phase II and phase IIIs are multinational trials.
Actuellement, pour les essais cliniques de médicaments, 20 p. 100 des demandes portent sur la phase I, 37 p. 100, sur la phase II, et 43 p. 100, sur la phase III. La majorité des demandes des phases II et III se rapportent à des essais internationaux.